Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27801684 | 0.80 | ALDH1A1 (0.48) | KAT2BALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL3633639 | 0.78 | KAT2B (0.57) | KAT2BALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL3632329 | 0.76 | TSHR (0.53) | KAT2BALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL3631173 | 0.76 | KAT2B (0.44) | KAT2BALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL7314606 | 0.76 | ALDH1A1 (0.52) | KAT2BALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL7306832 | 0.76 | ALDH1A1 (0.52) | KAT2BALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL4427648 | 0.73 | ALDH1A1 (0.71) | KAT2BALDH1A1TDP1TSHRCYP3A4 | |
| Butane SCHEMBL27499178 | 0.70 | ALDH1A1 (0.60) | KAT2BALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL671038 | 0.69 | ALDH1A1 (0.48) | KAT2BALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL3631141 | 0.69 | KAT2B (0.49) | KAT2BALDH1A1TDP1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | KAT2B 924/4885ALDH1A1 45/4885TDP1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.